Ország: Kanada
Nyelv: angol
Forrás: Health Canada
METHOCARBAMOL; IBUPROFEN
TEVA CANADA LIMITED
M03BA53
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
500MG; 200MG
TABLET
METHOCARBAMOL 500MG; IBUPROFEN 200MG
ORAL
18/40
OTC
CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS
Active ingredient group (AIG) number: 0248961001; AHFS:
CANCELLED POST MARKET
2021-08-12
1 | P a g e PRODUCT MONOGRAPH MUSCLE & BACK PAIN RELIEF WITH IBUPROFEN 500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS THERAPEUTIC CLASSIFICATION MUSCLE RELAXANT / ANALGESIC TEVA CANADA LIMITED. Date of Preparation: 30 Novopharm Court, May 1, 2013 Toronto, Ontario Canada, M1B 2K9 Control# 164010 2 | P a g e TABLE OF CONTENTS Clinical Pharmacology .............................................................................................................................. 3 Indications: ................................................................................................................................................ 7 Contraindications ...................................................................................................................................... 8 Warnings: .................................................................................................................................................. 8 Precautions .............................................................................................................................................. 12 Drug Interactions .................................................................................................................................... 13 Adverse Reactions .................................................................................................................................. 15 Symptoms and Treatment of Overdose ................................................................................................... 17 Dosage and Administration..................................................................................................................... 18 Pharmaceutical Information .................................................................................................................... 19 Composition: ........................................................................................................................................... 21 Availability of Dosage Forms .............. Olvassa el a teljes dokumentumot